Find a Doctor or Practice Location

You can also search for providers and practices at Penn Medicine Lancaster General Health or Princeton Health.

I am searching for a
Reset Form
Daniel J. Landsburg, MD

Daniel J. Landsburg, MD Physician

Medical Director of Infusion Services, Hospital of the University of Pennsylvania Vice Chief of Quality and Safety, Division of Hematology/Oncology Associate Professor of Clinical Medicine

Dr. Landsburg is employed by Penn Medicine.

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Clinical Specialties


  • Hematology

Programs & Centers:

Board Certification:

  • Hematology, 2014
  • Internal Medicine, 2011
  • Medical Oncology, 2014

Clinical Expertise:

  • Adult T-Cell Lymphoma
  • Bone Marrow Biopsy
  • Chronic Lymphocytic Leukemia
  • CNS Lymphoma
  • Cutaneous B Cell Lymphoma
  • Gray Zone Lymphoma
  • Hairy Cell Leukemia
  • HIV Lymphoma
  • Hodgkin Lymphoma
  • Immunotherapy
  • Intraocular Lymphoma
  • Large Granular Lymphocytic Leukemia
  • Mantle Zone Lymphoma
  • Marginal Zone Lymphoma
  • Mediastinal Lymphoma
  • Mucosa-Associated Lymphoid Tissue Lymphoma
  • Non-Hodgkin Lymphoma
  • Peripheral T-Cell Lymphoma
  • Sezary Syndrome
  • Small Lymphocytic Lymphoma
  • Transformed Lymphoma
  • Waldenstrom Macroglobulinemia (WM)
Show All Expertise

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oscar Health Plan of PA
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Temple University School of Medicine
Residency: Hospital of the University of Pennsylvania
Fellowship: Hospital of the University of Pennsylvania


American Society of Clinical Oncology, International American Society of Hematology, International National Comprehensive Cancer Network, National

Hospital Affiliation

Dr. Landsburg is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.


Description of Research Expertise:

Double-hit B cell lymphoma
MYC-altered B cell lymphoma
Diffuse large B cell lymphoma
Aggressive B cell lymphoma

Selected Publications:

Landsburg Daniel J, Ayers Emily C, Bond David A, Maddocks Kami J, Karmali Reem, Behdad Amir, Curry Madeira, Wagner-Johnston Nina D, Modi Dipenkumar, Ramchandren Radhakrishnan, Assouline Sarit E, Faramand Rawan, Chavez Julio C, Torka Pallawi, Mier Hicks Angel, Medeiros L Jeffrey, Li Shaoying: Poor outcomes for double-hit lymphoma patients treated with curative-intent second-line immunochemotherapy following failure of intensive front-line immunochemotherapy. British journal of haematology : 2019.

Emily C. Ayers, Shaoying Li, Jeffrey Medeiros, David A. Bond, Kami J. Maddocks, Pallawi Torka, Angel Mier Hicks, Madeira Curry, Nina D. Wagner-Johnston, Reem Karmali, Amir Behdad, Bita Fakhri, Brad S Kahl, Michael C Churnetski, Jonathon B. Cohen, Nishitha Reddy, Dipenkumar Modi, Radhakrishnan Ramchandren, Christina Howlett, Lori A. Leslie, Samuel Cytryn, Catherine Diefenbach, Rawan Faramand, Julio C. Chavez, Adam J Olszewski, Yang Liu, Stefan Klaus Barta, Dhruvika Mukhija, Brian T. Hill, Helen Ma, Jennifer E Amengual, Sunita Nathan, Sarit Assouline, Victor M. Orellana-Noia, Craig A. Portell, Ashwin Chandar, Kevin A. David, Anshu Giri, Brian T. Hess, and Daniel J. Landsburg: Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer 126 (2): 293-303,2019.

Landsburg Daniel J, Hughes Mitchell E, Koike Alexa, Bond David, Maddocks Kami J, Guo Ling, Winter Allison M, Hill Brian T, Ondrejka Sarah L, Hsi Eric D, Nasta Sunita D, Svoboda Jakub, Schuster Stephen J, Bogusz Agata M: Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy. Blood advances 3 (2): 132-135,2019.

Landsburg Daniel J, Kahl Brad S: Can We Exploit the Molecular Heterogeneity of Aggressive B Cell Lymphomas Into Effective New Therapies? Clinical lymphoma, myeloma & leukemia 19 (2): 65-67,2018.

Rhodes Joanna, Landsburg Daniel J: Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma. Current hematologic malignancy reports 13 (5): 356-368,2018.

Cherng Hua-Jay J, Sargent Rachel Lynn, Nasta Sunita Dwivedy, Svoboda Jakub, Schuster Stephen J, Mato Anthony R, Schrank-Hacker April, Morrissette Jennifer J D, Landsburg Daniel J: Interim PET/CT Result Is Not Predictive of Survival in Patients With MYC-rearranged Non-Burkitt Aggressive B-cell Lymphoma. Clinical lymphoma, myeloma & leukemia 18 (10): 673-678,2018.

Landsburg Daniel J: Advancing the management of double hit lymphoma. Oncotarget 8 (45): 78245-78246,2017.

Landsburg Daniel J, Falkiewicz Marissa K, Maly Joseph, Blum Kristie A, Howlett Christina, Feldman Tatyana, Mato Anthony R, Hill Brian T, Li Shaoying, Medeiros L Jeffrey, Torka Pallawi, Hernandez-Ilizaliturri Francisco, Reddy Nishitha M, Singavi Arun, Fenske Timothy S, Chavez Julio C, Kaplan Jason B, Behdad Amir, Petrich Adam M, Bast Martin A, Vose Julie M, Olszewski Adam J, Costa Cristiana, Lansigan Frederick, Gerson James N, Barta Stefan K, Calzada Oscar, Cohen Jonathon B, Lue Jennifer K, Amengual Jennifer E, Rivera Xavier, Persky Daniel O, Peace David J, Nathan Sunita, Cassaday Ryan D: Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35 (20): JCO2017722157,2017.

Landsburg Daniel J, Falkiewicz Marissa K, Petrich Adam M, Chu Benjamin A, Behdad Amir, Li Shaoying, Medeiros L Jeffrey, Cassaday Ryan D, Reddy Nishitha M, Bast Martin A, Vose Julie M, Kruczek Kimberly R, Smith Scott E, Patel Priyank, Hernandez-Ilizaliturri Francisco, Karmali Reem, Rajguru Saurabh, Yang David T, Maly Joseph J, Blum Kristie A, Zhao Weiqiang, Vanslambrouck Charles, Nabhan Chadi: Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. British journal of haematology 175 (4): 631-640,2016.

Landsburg Daniel J: Management of Patients with MYC-Altered Lymphomas Current Hematologic Malignancy Reports 11 (3): 208-17,2016.

Landsburg Daniel J, Petrich Adam M, Abramson Jeremy S, Sohani Aliyah R, Press Oliver, Cassaday Ryan, Chavez Julio C, Song Kevin, Zelenetz Andrew D, Gandhi Mitul, Shah Namrata, Fenske Timothy S, Jaso Jesse, Medeiros L Jeffrey, Yang David T, Nabhan Chadi: Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. Cancer 122 (4): 559-64,2015.

Landsburg Daniel J, Nasta Sunita D, Svoboda Jakub, Morrissette Jennifer J D, Schuster Stephen J: 'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients. British Journal of Haematology 166 (3): 369-74,2014.

Academic Contact Info

Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-182
3400 Civic Center Boulevard

Philadelphia, PA 19104
Phone: (215) 615-7361
Patient appointments: 800-789-7366